Page 47 - 84_02

cell features and correlates with adverse clinical
outcomes. Exp Hematol. 2009 Dec;37(12):1423-34.
61. Gerber JM, Smith BD, Ngwang B, Zhang H, Vala
MS, Morsberger L, et al. A clinically relevant
population of leukemic CD34(+)CD38(-) cells in
acute myeloid leukemia. Blood. 2012 Apr
12;119(15):3571-7.
62. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, et al. Glioma stem cells promote
radioresistance by preferential activation of the DNA
damage response. Nature. 2006;444(7120):756-60.
63. Dean M, Fojo T, Bates S. Tumour stem cells and drug
resistance. Nat Rev Cancer. 2005 Apr;5(4):275-84.
64. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura
H, Tanaka S, et al. Chemotherapy-resistant human
AML stem cells home to and engraft within the bone-
marrow endosteal region. Nat Biotechnol. 2007
Nov;25(11):1315-21.
65. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ,
Kulp AN, et al. Association of reactive oxygen species
levels and radioresistance in cancer stem cells. Nature.
2009 Apr 9;458(7239):780-3.
66. Colak S, Zimberlin CD, Fessler E, Hogdal L,
Prasetyanti PR, Grandela CM, et al. Decreased
mitochondrial priming determines chemoresistance of
colon cancer stem cells. Cell Death Differ. 2014
Jul;21(7):1170-7.
67. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY.
CD133+ HCC cancer stem cells confer
chemoresistance by preferential expression of the
Akt/PKB survival pathway. Oncogene. 2008 Mar
13;27(12):1749-58.
68. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella
E, Gatti L, et al. Highly tumorigenic lung cancer
CD133+ cells display stem-like features and are
spared by cisplatin treatment. Proc Natl Acad Sci U S
A. 2009 Sep 22;106(38):16281-6.
69. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti
F, Sette G, et al. Chemotherapy resistance of
glioblastoma stem cells. Cell Death Differ. 2006
Jul;13(7):1238-41.
70. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M,
Brown M, et al. CXCR1 blockade selectively targets
human breast cancer stem cells in vitro and in
xenografts. J Clin Invest. 2010 Feb;120(2):485-97.
71. Todaro M, Alea MP, Di Stefano AB, Cammareri P,
Vermeulen L, Iovino F, et al. Colon cancer stem cells
dictate tumor growth and resist cell death by
production of interleukin-4. Cell Stem Cell. 2007 Oct
11;1(4):389-402.
72. Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J,
Ngan L, et al. Colorectal cancer stem cells are
enriched in xenogeneic tumors following
chemotherapy. PLoS One. 2008;3(6):e2428.
73. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart
JW, Guba M, et al. Distinct populations of cancer
stem cells determine tumor growth and metastatic
162
Ruth M. Risueño
activity in human pancreatic cancer. Cell Stem Cell.
2007 Sep 13;1(3):313-23.
74. Oravecz-Wilson KI, Philips ST, Yilmaz OH, Ames
HM, Li L, Crawford BD, et al. Persistence of
leukemia-initiating cells in a conditional knockin
model of an imatinib-responsive myeloproliferative
disorder. Cancer Cell. 2009;16(2):137-48.
75. Baumann M, Krause M, Hill R. Exploring the role of
cancer stem cells in radioresistance. Nat Rev Cancer.
2008 Jul;8(7):545-54.
76. Jawad M, Seedhouse C, Mony U, Grundy M, Russell
NH, Pallis M. Analysis of factors that affect in vitro
chemosensitivity of leukaemic stem and progenitor
cells to gemtuzumab ozogamicin (Mylotarg) in acute
myeloid leukaemia. Leukemia. 2010 Jan;24(1):74-80.
77. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE.
Targeting of CD44 eradicates human acute myeloid
leukemic stem cells. Nat Med. 2006 Oct;12(10):1167-
74.
78. Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl
AG, Wilkinson L, et al. Monoclonal antibody-
mediated targeting of CD123, IL-3 receptor alpha
chain, eliminates human acute myeloid leukemic stem
cells. Cell Stem Cell. 2009 Jul 02;5(1):31-42.
79. Kharas MG, Okabe R, Ganis JJ, Gozo M, Khandan T,
Paktinat M, et al. Constitutively active AKT depletes
hematopoietic stem cells and induces leukemia in
mice. Blood. 2010 Feb 18;115(7):1406-15.
80. Passegue E, Wagner EF, Weissman IL. JunB
deficiency leads to a myeloproliferative disorder
arising from hematopoietic stem cells. Cell. 2004 Oct
29;119(3):431-43.
81. Koo S, Huntly BJ, Wang Y, Chen J, Brumme K, Ball
B, et al. Cdx4 is dispensable for murine adult
hematopoietic stem cells but promotes MLL-AF9-
mediated leukemogenesis. Haematologica. 2010
Oct;95(10):1642-50.
82. Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett
CA, Hassane DC, et al. An orally bioavailable
parthenolide analog selectively eradicates acute
myelogenous leukemia stem and progenitor cells.
Blood. 2007 Dec 15;110(13):4427-35.
83. Gal H, Amariglio N, Trakhtenbrot L, Jacob-Hirsh J,
Margalit O, Avigdor A, et al. Gene expression profiles
of AML derived stem cells; similarity to
hematopoietic stem cells. Leukemia. 2006
Dec;20(12):2147-54.
84. Koeffler HP. Is there a role for differentiating therapy
in non-APL AML? Best Pract Res Clin Haematol.
2010 Dec;23(4):503-8.
85. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem
cells, cancer, and cancer stem cells. Nature. 2001 Nov
1;414(6859):105-11.
86. Lobo NA, Shimono Y, Qian D, Clarke MF. The
biology of cancer stem cells. Annu Rev Cell Dev Biol.
2007;23:675-99.
@Real Academia Nacional de Farmacia. Spain